Owusu et al. [119] and others [35] have demonstrated that HGF drives resistance to anti-MET therapy in MET-amplified lung cancer cells (Figure 6), revealing that MET-amplified NSCLC cells become addicted to HGF upon MET inhibition. Here, HGF is linked to lung cancer.